For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

The incidence and mortality rate of esophageal cancer in China fell by around 4.5 percent annually, according to the figures ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune ...

"The number one thing I tell care partners is that they’re going to have emotions and it’s okay to feel sad. It’s okay to be ...

The American Lung Association in New York is inviting the New York City community to unite as one mighty force for lung ...

A new lung detection machine at CHRISTUS St. Frances Cabrini Hospital is helping doctors identify lung issues earlier.

Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...

Chemotherapy has been the standard for previously untreated advanced or metastatic HER2-mutant lung cancer. In this phase I ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.